Hard Gelatin Capsule Plant Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Hard gelatin capsule plant sits under India's strictest regulatory regime (CDSCO at the centre, state Drug Controllers, plus WHO-GMP and Schedule M). For ₹6.0 crore - ₹71 crore CapEx this DPR captures:

• PLI Bulk Drugs (₹15,000 cr) or PLI Medical Devices (₹3,420 cr) participation
• NABH / NABL accreditation if the project includes a clinical or diagnostic arm
• Manufacturing licence under the Drugs and Cosmetics Act 1940 (Form 25/28/28A by category)
• CDSCO + State Drug Controller dual approval for new formulations
• WHO-GMP and Schedule M revised standards compliance

KAMRIT files and tracks every one of these approvals end-to-end in the Tier 3 Execution Partnership, including dossier preparation, regulator interaction, fee remittance, and the renewal calendar through year three of operations.

<p>Hard gelatin capsules serve as the primary delivery vehicle for pharmaceutical formulations, nutraceuticals, and dietary supplements. Within the broader pharmaceutical sector, the hard gelatin capsule segment is a critical enabler, given that oral solid dosage forms remain the preferred administration route for the majority of generic and branded drugs. Indian domestic production of empty hard gelatin capsules is estimated at approximately 64 billion capsules, reflecting a robust base of domestic manufacturing activity.

The organized sector comprises large-scale, technologically advanced, and regulatory-compliant domestic and multinational players that control the majority of high-volume pharmaceutical and export-grade hard gelatin capsule manufacturing. The unorganized sector consists of numerous small-scale, regional, and local producers catering primarily to domestic generic formulations.</p><p>Key industrial hubs for capsule manufacturing in India are concentrated in Baddi, Ahmedabad, Hyderabad, and Haridwar. Gujarat, with hubs in Ahmedabad and Ankleshwar, serves as a primary pharmaceutical and gelatin consumption hub.

Telangana and Andhra Pradesh, centered around Hyderabad, act as a major bulk drug and finished formulation cluster. Himachal Pradesh's Baddi and Haridwar also host significant manufacturing activity. The animal-based gelatin segment commands a dominant 79.55% market share in India as of 2025, while pharmaceutical-grade gelatin is the fastest-growing sub-segment, expanding at 7.82% CAGR through 2031.</p><p>The empty hard gelatin capsule market was valued at USD 3.4 billion globally in 2025, scaling to USD 3.7 billion in 2026.

India's pharmaceutical capsule market as a whole is projected to grow at a CAGR of over 7% up to 2030. The supply chain is structured with upstream sourcing of bone pieces, hide, and ossein from slaughterhouses and tanneries providing raw pharmaceutical-grade gelatin, while plasticizers such as glycerin and sorbitol, purified water, and colorants are integrated into the upstream manufacturing cycle.</p>

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth
• Hospital capex expansion in Tier-2/3

<p>Modern hard gelatin capsule manufacturing plants employ highly automated production lines that deliver significantly higher throughput than earlier-generation equipment. Market data indicates that leading plant capacities range from 75,000 capsules per hour to 2 billion capsules annually, requiring specialized technical oversight for climate-controlled processing environments. Production speeds for modern automated lines have advanced considerably, with smaller-scale equipment such as automatic capsule making machines available at capacities of 40,000 units per hour, while mid-capacity plants target outputs of up to 150,000 capsules per hour.</p><p>Hard gelatin capsule manufacturing technology is categorized alongside alternative capsule technologies such as HPMC or vegetable-based capsules and pullulan capsules.

HPMC capsules are manufactured from plant cellulose, specifically wood pulp sourced from pine or poplar trees, and feature a moisture content of 3% to 8% compared to 13% to 16% for hard gelatin capsules. HPMC capsules are hypoallergenic, non-GMO, Kosher-certified, and Halal-certified, positioning them as an alternative for vegetarian and allergen-sensitive markets. Pullulan, another alternative, is a water-soluble polysaccharide offering distinct formulation advantages.</p><p>Plant and machinery CapEx for setting up a hard gelatin capsule manufacturing unit varies significantly by scale.

A standard dedicated hard gelatin capsule shell manufacturing unit was estimated at a pre-feasibility project cost of Rs. 95.9 million in 2021, comprising Rs. 81.3 million in fixed capital investment and Rs. 14.7 million in working capital. For smaller domestic-market-focused setups, total project costs range from Rs. 5 crores to Rs. 15 crores. Industrial machinery suppliers such as ACG Associated Capsules Pvt.

Ltd., Kevin Process Technologies Pvt. Ltd., and Pharmalab India Pvt. Ltd. provide turnkey and component solutions.

Labh Projects Private Limited offers hard gelatin capsule manufacturing plants starting at Rs. 3,500,000 for capacities up to 150,000 capsules per hour, while Herin Machinery of Ahmedabad supplies automatic capsule making machines priced at Rs. 650,000 for 40,000 units per hour.</p><p>Energy efficiency is emerging as a critical operational parameter. Modern pharmaceutical and hard gelatin capsule facilities target a 40% reduction in Scope 1 and Scope 2 emissions by 2030, with net-zero operations targeted by 2050. Baseline manufacturing data indicates that gelatin processing plants utilize an average electricity consumption of 1174.76 kWh per megagram and 22.39 GJ per megagram of thermal energy.

A standard production unit with an initial capacity of 75,000 to 180,000 packets per year requires approximately 16 direct employees, reflecting moderate labor intensity relative to capital investment.</p>

For a ₹20 crore mid-scale capsule plant project, KAMRIT recommends a debt-equity ratio of 70:30 leveraging the PLI scheme for bulk drugs and medical devices where capsule inputs qualify. SIDBI offers specific MSME healthcare financing schemes with a 75 basis points concession on base rate for GMP-certified plants, making SIDBI term loans at 8.5-9.0% the primary debt source. For working capital, HDFC and Axis Bank provide inventory finance against gelatin stock and receivables discounting against confirmed pharmaceutical offtake orders. SBI Healthcare finance desk has dedicated appraisal teams for pharma projects with turnaround time under 45 days. PMEGP loans up to ₹50 lakh are available for micro-enterprises through KVIC channels, while CGTMSE covers collateral-free portions up to ₹5 crore for units registered under MSME Udyam. State schemes in Gujarat, Maharashtra, and Himachal Pradesh offer 10-15% capital subsidies for pharma manufacturing units located in designated industrial areas. Working capital cycle for capsule plants typically runs 45-60 days given the 30-day gelatin procurement cycle and 45-day receivables from pharmaceutical formulation companies.

<p>Raw material supply volatility is the most significant operational risk facing hard gelatin capsule manufacturing plants. Over 75% of raw gelatin is derived from animal sources, specifically bone pieces, hide, and ossein from slaughterhouses and tanneries, making the supply chain inherently vulnerable to livestock supply fluctuations. Raw material price volatility has increased by 30%, while animal by-product regulatory restrictions have reduced effective supply by nearly 15%.

These supply-side constraints directly compress margins and introduce planning uncertainty, particularly for plants operating at high raw material cost exposure of 50% to 60% of total operating expenses.</p><p>Currency and import dependency risks are notable given that India imports a portion of its gelatin raw material and specialized equipment. The top supplier countries for gelatin imports to India include the United States and Bangladesh, among others. Fluctuations in exchange rates, international trade policies, and global gelatin pricing can materially affect production costs.

Additionally, specialized plant machinery for high-capacity automated lines may involve import dependence, exposing operators to currency risk and supply chain lead-time uncertainty.</p><p>Regulatory compliance represents a continuous operational risk. Manufacturing licenses under Form 25 and Form 28 issued by the State Licensing Authority, combined with DCGI approvals, require ongoing adherence to evolving standards. Microbial limits, moisture content specifications, and disintegration time requirements mandate rigorous quality control infrastructure.

Non-compliance can result in license suspension, product recalls, or export market exclusion, with severe financial and reputational consequences.</p><p>Competitive pressures from both organized and unorganized sector players create margin compression risks. The organized sector, comprising ACG, Sunil Healthcare, Natural Capsules, Nectar Lifesciences, and others, controls high-volume export-grade manufacturing and commands premium pricing. The unorganized sector, comprising numerous small-scale producers, competes aggressively on price for domestic generic formulations, potentially eroding market share for mid-sized operators without scale advantages or differentiated capabilities.</p><p>Technological obsolescence risk is present given rapid advancements in capsule manufacturing automation and alternative capsule technologies such as HPMC and pullulan.

Plants with older-generation equipment operating at lower capacities and higher utility consumption face a competitive disadvantage. Utility costs represent 20% to 25% of total operating expenses, and baseline data shows gelatin processing plants consume an average of 1174.76 kWh per megagram of electricity and 22.39 GJ per megagram of thermal energy. Plants that do not invest in energy-efficient technologies targeting the industry standard of 40% Scope 1 and Scope 2 emissions reduction by 2030 may face higher operating costs and potential regulatory penalties as environmental norms tighten.</p><p>Animal-based gelatin, which commands 79.55% of the Indian gelatin market as of 2025, faces growing substitution risk from plant-based alternatives.

HPMC capsules, with their lower moisture content, hypoallergenic properties, and certification advantages, are gaining market share in segments prioritizing vegetarian and allergen-free products. A sustained shift toward plant-based capsules could devalue investments in gelatin-specific manufacturing infrastructure.</p>